Anti-Fibrinolytic Drugs - Indonesia

Indonesia

In Indonesia, the Anti-Fibrinolytic Drugs market is anticipated to witness a significant growth in revenue, projected to reach US$50.53m in 2024.
This market is expected to exhibit a steady annual growth rate of 5.30% from 2024 to 2029, leading to a market volume of US$65.43m by 2029.
When compared on a global scale, United States is anticipated to generate the highest revenue in this market, with an estimated value of US$9,858.00m in 2024.
Indonesia's growing healthcare industry is witnessing an increased demand for anti-fibrinolytic drugs, driven by a rise in cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Fibrinolytic Drugs in Indonesia has been on the rise in recent years.

Customer preferences: Indonesian customers are increasingly turning towards Anti-Fibrinolytic Drugs due to the high prevalence of bleeding disorders in the country. The growing awareness about the benefits of these drugs in controlling excessive bleeding during surgeries and injuries has also contributed to the surge in demand.

Trends in the market: The Anti-Fibrinolytic Drugs market in Indonesia is witnessing a shift towards generic drugs due to their cost-effectiveness. The patent expiry of several branded drugs has opened up opportunities for local manufacturers to enter the market with their generic versions. This has intensified competition and led to a decrease in prices, making the drugs more accessible to the masses.

Local special circumstances: Indonesia has a large population of hemophilia patients, which is a major driver of the Anti-Fibrinolytic Drugs market. The lack of access to advanced medical facilities in many parts of the country has also led to an increase in demand for these drugs, as they can be used in emergency situations.

Underlying macroeconomic factors: The Indonesian government's efforts to improve healthcare infrastructure and increase access to medical facilities have supported the growth of the Anti-Fibrinolytic Drugs market. The rising disposable income of the middle class has also contributed to the increase in demand for these drugs. However, the market is still facing challenges related to the availability of skilled healthcare professionals and the high cost of advanced medical treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.